Issue 151 • February 2025

The biggest challenges clinical trials will face in 2025

Evolving research plans, regulatory guidance and an increasingly diverse pool of investigational drugs await the clinical trial sector in 2025.

Briefing

JPM 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance

Feature

ADCs breach barriers to become mainstream cancer treatment

Feature

WHO trial guidance goes beyond race and gender when tackling diversity

Analyst Comment

Is biopharma M&A poised for a rebound?